<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789724</url>
  </required_header>
  <id_info>
    <org_study_id>VCU-ART</org_study_id>
    <nct_id>NCT00789724</nct_id>
  </id_info>
  <brief_title>Anakinra to Prevent Post-infarction Remodeling</brief_title>
  <acronym>VCU-ART</acronym>
  <official_title>Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thousands of patients die daily from early and late complications of a heart attack (acute
      myocardial infarction, AMI). Patients surviving AMI remain at high risk of death from adverse
      cardiac remodeling (dysfunction and enlargement of the heart) leading to heart failure
      (weakening of the heart).

      Current interventions proven to reduce adverse remodeling and progression to heart failure
      include early reperfusion (restoring blood flow to the heart muscle) and long-term use of
      medicines that block the effects of hormones (such as angiotensin II, norepinephrine and
      aldosterone) involved in adverse remodeling. Despite these treatments, however, many patients
      continue to develop heart failure within 1 year of AMI. These patients are at very high risk
      of death.

      Numerous changes occur in the hearts of patients after AMI that lead to adverse remodeling.
      Ischemia (lack of oxygen) and infarction (cell damage) lead to increased interleukin-1 (IL-1)
      production in the heart. IL-1 plays a critical role in adverse cardiac remodeling by
      coordinating the inflammatory pathway (leading to wound healing) and apoptotic pathway
      (leading to cell death).

      In opposition to IL-1 activity, the human body produces a natural IL-1 receptor antagonist
      that blocks the effects of IL-1. The drug form of this IL-1 receptor antagonist (anakinra) is
      currently FDA approved for the treatment of rheumatoid arthritis, an inflammatory disease
      characterized by excessive IL-1 activity. Experimental studies show that anakinra is able to
      prevent cardiac remodeling and improve survival in mice after AMI.

      We hypothesize that anakinra will show similar benefits in human patients by preventing
      adverse remodeling and heart failure after AMI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.</measure>
    <time_frame>10-14 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in the Percentage of Patients With Any of the Following : a) End-systolic or End-diastolic Volume Index Increase &gt;10%; b) Ejection Fraction Decrease &gt;10%; c) E/E'&gt;15 at Follow up</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in Change in the Number of Circulating Endothelial Progenitor Cells From Baseline to Follow up Exam</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in Change in Serum BNP Levels, C-reactive Protein, and Hemoglobin A1c% From Baseline to Follow up</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in the Incidence of Significant Cardiac Arrhythmias in the Acute Phase</measure>
    <time_frame>48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in the Number of Adverse Effects Including a) All Events; b) All Events Requiring Unblinding of the Treatment; c) All Events Requiring Early Termination of the Intervention</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in Change in Oxygen Uptake Kinetics From Baseline to Follow up Exam at Submaximal Cardiopulmonary Exercise Test</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in Change in E/E' Ratios and Myocardial Performance (Tei) Indices From Baseline to Follow up Exam at Transthoracic Echo-color-Doppler Cardiac Exam</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference Between the 2 Arms in Change in End-diastolic Volume Indices and Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</measure>
    <time_frame>10-14 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>ST Segment Elevation Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg given daily by subcutaneous injection for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.67 ml of NaCl 0.9% solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>100 mg daily subcutaneous injection for 14 days</description>
    <arm_group_label>Anakinra</arm_group_label>
    <other_name>Kineret (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.67 ml of NaCl 0.9% subcutaneously daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Acute (&lt;24 hours) onset of chest pain

          -  New or presumably new ST elevation on ECG

          -  Planned coronary angiography for percutaneous revascularization

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Late presentation (&gt;24 hours)

          -  Unsuccessful revascularization or urgent coronary bypass surgery

          -  Hemodynamic instability

          -  End-stage congestive heart failure (AHA/ACC stage C/D, NYHA class IV)

          -  Preexisting severe LV dysfunction (LVEF&lt;20%) or severe valvular disease

          -  Severe asthma

          -  Pregnancy ( pre-enrollment pregnancy test)

          -  Contraindications to cardiac MRI or cardiac angiography

          -  Severe coagulopathy (INR&gt;2.0, Platelet count&lt;50,000/mm3)

          -  Severe renal insufficiency (creatinine clearance &lt;30 ml/min/m2)

          -  Recent (&lt;14 days) use of anti-inflammatory drugs (NSAIDS excluded)

          -  Chronic inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>July 30, 2010</results_first_submitted>
  <results_first_submitted_qc>July 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2010</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment started in November 2008. During the first 4 months, 33 patients admitted with STEMI were screened and 10 patients were enrolled. One patient withdrew consent to the study on day 2 prior to all assessment and was excluded. The Institutional Review Board then approved enrollment of an additional patient who was enrolled in May 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg given daily by subcutaneous injection for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.67 ml of NaCl 0.9% solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg given daily by subcutaneous injection for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.67 ml of NaCl 0.9% solution</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="13"/>
                    <measurement group_id="B2" value="52" spread="15"/>
                    <measurement group_id="B3" value="48" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.</title>
        <time_frame>10-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg given daily by subcutaneous injection for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.67 ml of NaCl 0.9% solution</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.</title>
          <units>mL/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" lower_limit="-4.5" upper_limit="-1.2"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in the Percentage of Patients With Any of the Following : a) End-systolic or End-diastolic Volume Index Increase &gt;10%; b) Ejection Fraction Decrease &gt;10%; c) E/E'&gt;15 at Follow up</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in Change in the Number of Circulating Endothelial Progenitor Cells From Baseline to Follow up Exam</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in Change in Serum BNP Levels, C-reactive Protein, and Hemoglobin A1c% From Baseline to Follow up</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in the Incidence of Significant Cardiac Arrhythmias in the Acute Phase</title>
        <time_frame>48 hours</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in the Number of Adverse Effects Including a) All Events; b) All Events Requiring Unblinding of the Treatment; c) All Events Requiring Early Termination of the Intervention</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in Change in Oxygen Uptake Kinetics From Baseline to Follow up Exam at Submaximal Cardiopulmonary Exercise Test</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in Change in E/E' Ratios and Myocardial Performance (Tei) Indices From Baseline to Follow up Exam at Transthoracic Echo-color-Doppler Cardiac Exam</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference Between the 2 Arms in Change in End-diastolic Volume Indices and Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging</title>
        <time_frame>10-14 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg given daily by subcutaneous injection for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.67 ml of NaCl 0.9% solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Abbate, MD, PhD</name_or_title>
      <organization>VCU Pauley Heart Center</organization>
      <phone>8048280513</phone>
      <email>aabbate@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

